Radiopharm Theranostics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAD.AX research report →
Price Chart
About the company
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic.
- CEO
- Riccardo Canevari
- IPO
- 2021
- Employees
- 14
- HQ
- Carlton, VIC, AU
Get TickerSpark's AI analysis on RAD.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $23.65M
- P/E
- -0.65
- Fwd P/E
- 1.31
- PEG
- -0.00
- P/S
- 1.92
- P/B
- 0.68
- EV/EBITDA
- 0.25
- Div Yield
- 0.00%
- Gross Margin
- 172.70%
- Op Margin
- -402.78%
- Net Margin
- -363.95%
- ROE
- -93.08%
- ROIC
- -59.92%
Latest fiscal year · YoY change
- Revenue
- $13.40M+4378.3%
- Gross Profit
- $9.81M+146.0%
- Op Income
- $-38,173,865
- Net Income
- $-36,703,089+23.5%
- EPS
- $-0.02+85.3%
- OCF Growth
- -59.5%
- FCF Growth
- -59.5%
- 52W High
- $0.04
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- 0.77
- RSI (14)
- 28
- Avg Volume
- 6.38M
No earnings-call transcripts are available for RAD.AX yet.
- Free Float
- 111.2%
- Shares Outstanding
- 2.36B
- Float Shares
- 2.63B
Our RAD.AX coverage
Recent articles, reports, and earnings notes.
No research on RAD.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RAD.AX report →Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
globenewswire.com · Aug 17
Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial
proactiveinvestors.com · Mar 27
Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial
proactiveinvestors.com · Mar 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.